Aspirin in cardiovascular disease.

Area of Science:

• Cardiovascular Pharmacology
• Thrombosis and Hemostasis

Background:

• Aspirin's antithrombotic effects are mainly due to irreversible platelet cyclo-oxygenase inhibition.
• This blockade reduces platelet thromboxane synthesis, a key factor in thrombosis.

Purpose of the Study:

• To review the efficacy of aspirin in preventing various vaso-occlusive events.
• To analyze aspirin's role in secondary prevention of myocardial infarction, unstable angina, and stroke.
• To evaluate aspirin's effectiveness in preventing graft occlusion and its use in prosthetic devices.

Main Methods:

• Analysis of multiple placebo-controlled trials and studies investigating aspirin's effects on platelet function and clinical outcomes.
• Dose-ranging studies were examined for efficacy in different cardiovascular conditions.

Main Results:

• Aspirin significantly depresses platelet thromboxane formation even at low doses (20mg daily).
• Evidence suggests aspirin is beneficial in secondary prevention of myocardial infarction and unstable angina.
• Aspirin (100-975mg daily) prevents early coronary artery bypass graft occlusion, especially when initiated within 24 hours.
• High-dose aspirin (990-1300mg daily) is effective in preventing stroke and death in patients with transient ischemic attacks.

Conclusions:

• Aspirin demonstrates broad efficacy in preventing thrombotic events across various cardiovascular conditions.
• Optimal aspirin dosage varies, requiring further research for specific patient populations and prosthetic applications.
• While effective, aspirin alone is insufficient for preventing thromboembolic complications in prosthetic heart valves and may increase bleeding risk with anticoagulants.